AR132494A1 - Aglutinantes de trop2 y conjugados de estos - Google Patents
Aglutinantes de trop2 y conjugados de estosInfo
- Publication number
- AR132494A1 AR132494A1 ARP240101018A ARP240101018A AR132494A1 AR 132494 A1 AR132494 A1 AR 132494A1 AR P240101018 A ARP240101018 A AR P240101018A AR P240101018 A ARP240101018 A AR P240101018A AR 132494 A1 AR132494 A1 AR 132494A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- variable domain
- trop2
- antibody
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen aglutinantes de TROP2 y variantes de estos. En una forma de realización específica, se describen los aglutinantes de TROP2 que son anticuerpos que se unen preferentemente a células TROP2 de alta expresión sobre las células de TROP2 de baja expresión y conjugados de estos que comprenden los aglutinantes de TROP2 conjugados con una carga útil. Reivindicación 1: Un conjugado anticuerpo-fármaco (ADC) que comprende un anticuerpo o un fragmento de unión al antígeno que se une específicamente a TROP2 humano conjugado con una carga útil de ligador-monometillauristatina E (ligador-MMAE), en donde el anticuerpo comprende dos cadenas pesadas, donde cada cadena pesada comprende un dominio variable y un dominio constante, el dominio variable comprende una región determinante de la complementariedad (CDR) H1, una CDRH2, y una CDRH3, y dos cadenas livianas, donde cada cadena liviana comprende un dominio variable y un dominio constante, el dominio variable comprende una CDRL1, una CDRL2, y una CDRL3, donde la CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, y CDRL3, respectivamente, comprenden la secuencia de aminoácidos NYGMN (SEQ ID Nº 4), WINTYTGEPTYTDDFKG (SEQ ID Nº 5), GGFGSSYWYFDV (SEQ ID Nº 6), KASQDVSIAVA (SEQ ID Nº 7), SASDRYT (SEQ ID Nº 10) y QQHYITPLT (SEQ ID Nº 9). Reivindicación 21: Una composición que comprende el ADC de acuerdo con cualquiera de las reivindicaciones 1 a 20 y un portador farmacéuticamente aceptable. Reivindicación 34: Un conjugado anticuerpo-fármaco (ADC) que comprende un anticuerpo que se une específicamente a un TROP2 humano conjugado con una carga útil de ligadormonometilauristatina E (ligador-MMAE), en donde el anticuerpo comprende dos cadenas pesadas, en donde cada cadena pesada comprende un dominio variable y un dominio constante, en donde el dominio variable comprende la secuencia de aminoácidos de SEQ ID Nº 14, y dos cadenas livianas, en donde cada cadena liviana comprende un dominio variable y un dominio constante, donde el dominio variable comprende la secuencia de aminoácidos de SEQ ID Nº 15. Reivindicación 45: Una composición que comprende el ADC de acuerdo con cualquiera de las reivindicaciones 34 a 44 y un portador farmacéuticamente aceptable. Reivindicación 58: Un anticuerpo o fragmento de unión al antígeno de este que se une específicamente a TROP2 humano, que comprende: un dominio variable de la cadena pesada que comprende una CDRH1, una CDRH2 y una CDRH3, y un dominio variable de la cadena liviana que comprende una CDRL1, una CDRL2 y una CDRL3, en donde la CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 y CDRL3, respectivamente, comprenden la secuencia de aminoácidos NYGMN (SEQ ID Nº 4), WINTYTGEPTYTDDFKG (SEQ ID Nº 5), GGFGSSYWYFDV (SEQ ID Nº 6), KASQDVSIAVA (SEQ ID Nº 7), SASDRYT (SEQ ID Nº 10) y QQHYITPLT (SEQ ID Nº 9). Reivindicación 88: Un anticuerpo o fragmento de unión al antígeno de este que se une específicamente a TROP2 humano que comprende un dominio variable de la cadena pesada que comprende la secuencia de aminoácidos de SEQ ID Nº 14 y un dominio variable de la cadena liviana que comprende la secuencia de aminoácidos de SEQ ID Nº 15.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363497994P | 2023-04-24 | 2023-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132494A1 true AR132494A1 (es) | 2025-07-02 |
Family
ID=91129977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101018A AR132494A1 (es) | 2023-04-24 | 2024-04-22 | Aglutinantes de trop2 y conjugados de estos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240358847A1 (es) |
| CN (1) | CN121398855A (es) |
| AR (1) | AR132494A1 (es) |
| AU (1) | AU2024261810A1 (es) |
| CO (1) | CO2025014694A2 (es) |
| IL (1) | IL324043A (es) |
| MX (1) | MX2025012694A (es) |
| TW (1) | TW202506193A (es) |
| WO (1) | WO2024226410A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2235269C (en) | 1995-10-19 | 2006-09-19 | Bristol-Myers Squibb Company | Monoclonal antibody br110 and uses thereof |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| EP2287201B1 (en) | 2002-03-01 | 2018-12-12 | Immunomedics, Inc. | RS7 antibodies |
| EP2258392A1 (en) | 2002-11-08 | 2010-12-08 | Ablynx N.V. | Method of administering therapeutic polypeptides |
| MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US7420041B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| CN104231082B (zh) | 2007-05-24 | 2018-12-21 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| MX2010005783A (es) | 2007-11-27 | 2010-08-10 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. |
| EP2594589A1 (en) | 2010-06-10 | 2013-05-22 | Sapporo Medical University | ANTI-Trop-2 ANTIBODY |
| WO2013066765A1 (en) | 2011-11-01 | 2013-05-10 | Merck Sharp & Dohme Corp. | Mutation of tup1 in glycoengineered yeast |
| CA2854720C (en) | 2011-11-11 | 2018-12-18 | Rinat Neuroscience Corp. | Antibodies specific for trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| JP6130517B2 (ja) * | 2013-12-25 | 2017-05-17 | 第一三共株式会社 | 抗ｔｒｏｐ２抗体−薬物コンジュゲート |
-
2024
- 2024-04-22 AR ARP240101018A patent/AR132494A1/es unknown
- 2024-04-22 TW TW113114861A patent/TW202506193A/zh unknown
- 2024-04-22 US US18/642,038 patent/US20240358847A1/en active Pending
- 2024-04-22 WO PCT/US2024/025622 patent/WO2024226410A1/en active Pending
- 2024-04-22 AU AU2024261810A patent/AU2024261810A1/en active Pending
- 2024-04-22 CN CN202480041805.2A patent/CN121398855A/zh active Pending
-
2025
- 2025-10-19 IL IL324043A patent/IL324043A/en unknown
- 2025-10-23 MX MX2025012694A patent/MX2025012694A/es unknown
- 2025-10-23 CO CONC2025/0014694A patent/CO2025014694A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL324043A (en) | 2025-12-01 |
| WO2024226410A1 (en) | 2024-10-31 |
| US20240358847A1 (en) | 2024-10-31 |
| AU2024261810A1 (en) | 2025-11-13 |
| MX2025012694A (es) | 2025-11-03 |
| CO2025014694A2 (es) | 2025-11-07 |
| CN121398855A (zh) | 2026-01-23 |
| TW202506193A (zh) | 2025-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2747735C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2022191301A5 (es) | ||
| JP2020516240A5 (es) | ||
| PE20221869A1 (es) | Moleculas de union a antigeno biespecificas dirigidas a ox40 y fap | |
| RU2011105062A (ru) | Нейтрализующие антитела против вируса гриппа а и их использование | |
| AR123212A1 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| IL290591B1 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| CO6251370A2 (es) | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma | |
| HRP20170374T1 (hr) | Biološki proizvodi | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| AR082194A1 (es) | Anticuerpos anti-ron | |
| PE20221151A1 (es) | Anticuerpos anti-cd96 y sus metodos de uso | |
| PE20231386A1 (es) | Anticuerpos biespecificos contra ceacam5 y cd47 | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| JP2024109911A5 (es) | ||
| ZA202211246B (en) | Bispecific antibody | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| AR131143A1 (es) | Conjugados anticuerpo-fármaco anti-cea y métodos de uso | |
| JP2017511152A5 (es) | ||
| JP2020533382A5 (es) | ||
| AR125130A1 (es) | Conjugados de amatoxina y anticuerpo específicos de linfocitos b |